Seventh Framework Programme and European Commission logos

Advancing the development of life-saving drugs for cardiovascular diseases

CarTarDis cardiovascular target validation results published in Circulation

November 28, 2017

We are proud to announce that the results of the validation of the selected CarTarDis targets have been and will be disseminated in scientific manuscripts and posters. The abstracts of the most recent posters, presented at the American Heart Association conference in Anaheim, CA in November 2017, have been published in Circulation, November 14, 2017, Volume […]

Continue reading…

CarTarDis cardiovascular target validation workflow poster at EATRIS

November 28, 2017

Directed by the experienced pharmaceutical scientists in our team and advised by experienced drug developers and entrepreneurs in our External Advisory Board, CarTarDis designed a rational approach to accurately reflect the pharmaceutical process, adopting best practices from pharmaceutical industry from its start. First, available and emerging molecular data from three large independent cardiovascular cohorts was […]

Continue reading…

CarTarDis consortium official end date

November 28, 2017

The EC FP7 funded project CarTarDis (Cardiovascular Target Discovery) aimed to apply the high quality expertise and resources within its multi-partner consortium to discover novel therapeutic drug targets with a high level of clinical correlation to cardiovascular disease (CVD). The project adopted a strong pharmaceutical work flow in which the 13 consortium partners formed a […]

Continue reading…

CarTarDis dissemination activities fall 2017

August 21, 2017

Our CarTarDis collaborative project is near it’s end. With only a few weeks to go, and many exciting results of our activities becoming available in these weeks, we have a number of dissemination activities planned. We submitted several abstracts and are pleased to announce that CarTarDis will be represented by five poster presentations at two […]

Continue reading…

Heart@Target, joint meeting of three FP7 consortia on Cardiovascular research.

October 2, 2016

Three consortia of EU FP7 projects which are focused on identification and validation of new targets for drugs in cardiovascular disease organized a joint meeting in Zandvoort, The Netherlands on Tuesday the 27th and Wednesday 28th of September 2016.  With 60 participants from the three consortia,  represented by researchers from academia, several SME’s and big […]

Continue reading…

Cartardis partner Imabiotech presented poster ‘Multimodal Analysis and Mass Spectrometry Imaging of Atherosclerotic Plaque Tissue’ at the 2016 ASMS meeting

August 24, 2016

Poster CarTarDis Imabiotech ASMS 2016 Within the CartarDis project we evaluate  several CVD targets  and their mechanism of involvement in the development of CVD is studied with  multimodal molecular imaging techniques. Preliminary data obtained within the CarTarDis project showed that mechanisms related to lipid metabolism and inflammation are genetically and functionally linked to cardiovascular disease […]

Continue reading…

A systematic evaluation of the cellular innate immune response during the process of human atherosclerosis, paper supported by CarTarDis published by AHA

August 16, 2016

The concept of innate immunity is well recognized within the spectrum of atherosclerosis, which is primarily dictated by macrophages. Although current insights to this process are largely based on murine models, there are fundamental differences in the atherosclerotic microenvironment and associated inflammatory response relative to humans. In this light, Cartardis partner, LUMC characterized the cellular […]

Continue reading…

Paper on cardiac hypertrophy published by Umeå University

June 3, 2016

Cardiac hypertrophy and decreased high-density lipoprotein cholesterol in Lrig3-deficient mice. This interesting paper was financially supported by CarTarDis and published by partner  Umeå University in Am J Physiol Regul Integr Comp Physiol (March 23, 2016). Genetic factors confer risk for cardiovascular disease. Recently, large genome-wide population studies have shown associations between genomic loci close to LRIG3 […]

Continue reading…

PolyGene presented poster ‘Novel Glucocorticoid-based Gene Regulation System’ at Transgenic Technology Meeting

April 6, 2016

Polygene presented a poster entitled ‘Novel Glucocorticoïd-based Gene Regulation System’ the 13th Transgenic Technology Meeting in Prague, held March 20-23 2016 and organized by the International Society of Transgenic Technologies (ISTT) (http://www.transtechsociety.org/tt2016/). Over 600 scientists from all over the world attended this much sought-after meeting, and PolyGene was participating with four representatives. The program was dense with full […]

Continue reading…

New publication supported by CarTarDis published by Diabetes care

September 28, 2015

A peer rewiewed publication entitled ‘Effects of metformin on metabolite profiles and LDL cholesterol in patients with Type 2 Diabetes’ was published by the journal Diabetes Care few weeks ago. This publication was financially supported by CarTarDis. CarTarDis partner HMGU, CarTarDis team members Stefan Brandmeier, Rui-Wang Sattler and Thomas Meitinger significantly contributed to this exciting paper. The publication of […]

Continue reading…